The FDA approved Opdualag on the strength of the ... BMS' notoriously hard to tolerate CTLA4 checkpoint inhibitor – which has been approved as a monotherapy for melanoma since 2011 and as ...

Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients.

would be the first PD-1/PD-L1 checkpoint inhibitor to be approved for SCAC, providing Incyte with a niche indication to grow the drug without competition. That will be important, as retifanlimab ...

Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.

progressing on checkpoint inhibitors (QUILT-3.055): Anticipated BLA submission in 2025 with ongoing randomized Phase 3 trial in NSCLC patients who have failed checkpoint inhibitors (ResQ201A-NSCLC ...

Suzetrigine is the first new painkiller approved in the US since Celebrex, a type of nonsteroidal anti-inflammatory drug called a Cox-2 inhibitor, which was approved in 1998. Multiple parts of the ...

ImmunityBio will part with 10 employees this quarter. Last fall, it cut 31 employees. The moves come as the biotech works to ...

Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...